Dosing for all mice was performed during the day within an hour. Mouse euthanasia was 1 1 1 performed by exposure to increasing concentrations of carbon dioxide gas (as above). To were performed on plasma samples at the Shared University Research Facility, UoE. Serum was collected from healthy volunteers (n = 11) and APAP overdose patients injury. Blood samples were centrifuged at 1000g for 15 minutes at 4°C and the supernatant 1 2 2 6 was separated into aliquots and stored at -80°C prior to analysis. The protocol was approved Genomic and cell-free DNA extraction and quantitation 1 2 6
Genomic DNA (gDNA) was extracted from frozen tissue samples using DNEasy blood and 1 2 7 tissue kit (QIAGEN) and quantified using the Qubit dsDNA Broad Range assay kit (Thermo 1 2 8
Fisher Scientific) according to manufacturer's instructions. cfDNA was extracted from 1 2 9 plasma using the QIAamp circulating nucleic acid kit (QIAGEN) according to the 1 3 0 manufacturer's instructions. cfDNA from clinical samples and mice was quantified using a 1 3 1 single locus qPCR assay on the beta-actin (ACTB / Actb) gene [33, 34] . Fragment analysis of 1 3 2 cfDNA was performed using Agilent DNA Bioanalyser. (Additional File 3: Table S1 ). Cre recombination was analysed in gDNA of tissue-specific knockout mice using ddPCR to 1 5 7 ensure successful recombination in the target tissue and check for specificity of Cre 94°C denaturation and 60s at 60°C), and a 10-min inactivation step at 98 °C. The metric used 1 6 5 to show Cre recombination was percentage recombination (1lox%).
Analysis of liver-specific methylation fragments in human cfDNA 1 6 9
The contribution of liver tissue to cfDNA in clinical samples was analysed using a Non-parametric statistical methods were performed on datasets to account for small sample and to compare percentage of recombination of the floxed mT/mG gene in mouse tissues.
Statistical dependence between biomarkers were assessed using Spearman's rank correlation 1 8 1 coefficient. We designed and validated a ddPCR assay to quantify recombination in the floxed mT/mG 1 8 6
gene. Amplification of gDNA was performed to demonstrate specificity for each target allele 1 8 7 ( Fig. 1a and b) . Amplification of 2 lox gDNA with the 1lox assay showed no positive 1 8 8 droplet ( Fig. 1a) . Amplification of the 1lox gDNA with the 2lox assay showed 13 positive 1 8 9 droplets out of a total of 16467 (less than 0.1%) ( Fig. 1b ). Assay sensitivity was tested using 1 9 0 a dilution series of target alleles to show that the assay reproducibly quantifies less than 30 1 9 1 target alleles ( Fig. 1c) . Non-specific amplification was not observed in C57BL/6 background 1 9 2 gDNA, nor in the water negative control. Analysis of DNA recombination in mouse tissues 1 9 5
Cre recombination was confirmed in expected tissues using ddPCR ( Fig. 2a) and
fluorescence microscopy based on the expression of the mT/mG reporter gene ( Fig. 2b) . To 1 9 7 9 check for specificity of Cre recombination, we performed ddPCR on gDNA extracted from 1 9 8 16 tissue types for each knockout line. Highest specificity was found in hepatocyte and 1 9 9 cardiomyocyte knockout lines, where recombination was observed in liver and heart, 2 0 0 respectively, with minimal recombination in other tissues (Fig. 2c) . Specificity of Cre 2 0 1 recombination was more variable, but generally lower in the other knockout lines 2 0 2 (Additional File 4: Figure S3 ). To determine the tissue origins of cfDNA, we analysed cfDNA from the six tissue-specific 2 0 6 knockout lines using ddPCR. Plasma from 10 or more mice for each knockout line was 2 0 7 pooled prior to cfDNA extraction, to account for the small circulating blood volume of from each line by ddPCR ( Fig. 3a) . DNA fragment analysis confirmed the expected cfDNA 2 1 1 fragment size profile which followed the mono-, di-and tri-nucleosome pattern associated 2 1 2 with apoptosis, with larger cfDNA fragments most likely due to tissue necrosis and lysis 2 1 3 ( Fig. 3b ).
1 4
Contribution of different cell types to cfDNA was quantified by counting the number of 1lox 2 1 5 and 2lox alleles in the cfDNA of mice for each knockout line and subsequently the 2 1 6 percentage recombination (1lox%) for each of the knockout lines was calculated ( Fig. 3c) .
Absolute measurement of cfDNA showed that myeloid, lymphoid and erythroid lineages 2 1 8
were the major contributors to the levels of cfDNA in healthy mice, contributing 39.7%, 27.8% and 10.7% respectively, with a small contribution from hepatocytes (4.2%). Both cardiomyocyte and striated muscle cells had undetectable contribution to the levels of cfDNA 2 2 1 ( Fig. 3d) . To validate tissue-specific knockout mice as a model system for studying the tissue origins of 2 2 5 cfDNA, we measured hepatocyte-specific cfDNA levels after APAP overdose in hepatocyte-2 2 6 specific knockout mice. The optimal timepoint for sample collection was determined using 2 2 7 C57BL/6 mice after APAP administration. Following APAP administration, mice developed of liver injury, including loss of mobility or abnormal respiration. We assayed plasma for injections. An increase of the liver biomarkers, ALT and AST, and histological analysis of 2 3 8 mouse liver tissues confirmed the presence of liver injury (Fig. 4) . Furthermore, in non-treated healthy mice (Fig.4g, Additional File 7: Figure S6 ). To demonstrate potential applicability of our findings to APAP overdose in humans, we were not exhibiting clinically apparent liver injury based on serum ALT levels (Additional 2 4 8
File 8: Table S2 ). On average, the concentration of cfDNA in the APAP overdose patients increased by ~126-fold (Fig. 5a) . In patients with clinically apparent liver injury (high ALT), 2 5 0 total cfDNA increased by ~234-fold, whereas patients without clinically apparent liver injury 2 5 1 (normal ALT) demonstrated mean total cfDNA increase of ~18-fold compared to healthy 2 5 2 volunteers (Fig. 5a) . The increase in total cfDNA following APAP overdose in patients was 2 5 3 consistent with the increase in cfDNA following APAP in C57BL/6 and hepatocyte-specific To further assess the utility of cfDNA as a clinical biomarker, we compared the serum higher in all patients with APAP overdose than in healthy volunteers, although two samples, (cfDNA = 188.17) showed similar cfDNA concentrations (Fig. 5b) . Total concentration of <0.01) with the ( Fig. 5c ).
6 4
Specific analysis of liver contributions to the cfDNA pool, measured by ddPCR, showed the 2 6 5 percentage of liver-specific cfDNA fragments increased by ~175-fold in patients with 2 6 6 clinically apparent liver injury compared to healthy volunteers, but no increase in liver-2 6 7 specific cfDNA was observed in overdose patients without clinically apparent liver injury 2 6 8 (normal ALT) ( Fig. 5d, e ). Although GLDH levels were increased in APAP overdose patient with normal ALT, analysis of liver-specific cfDNA indicated that the cfDNA did not 2 7 0 originate from liver tissue (Fig. 5f ). Our study demonstrates the utility of tissue-specific knockout mouse models as a platform to 2 7 4 examine the tissue origins of cfDNA. Here, we present the first absolute, direct measurement 2 7 5 of the tissue origins of cfDNA in healthy mice, as well as post-APAP overdose. Our data 2 7 6
show that hematopoietic cells, including myeloid, lymphoid and erythroid cells, are the major 2 7 7 components of cfDNA in the healthy state, with a minor contribution from liver and no design may therefore be more accurate and less error-prone than indirect relative methods.
8 6
We also demonstrate the applicability of this model system in a pathological scenario. The hepatocyte-specific cfDNA after APAP overdose demonstrate the sensitivity of the model 2 9 0 system for detecting perturbations in the origins of cfDNA arising from external stimuli. The 2 9 1 study is the first to show the contribution of a specific tissue to the pool of cfDNA using 2 9 2 tissue-specific knockout mice, thereby serving as a generic proof of concept for conditions. This may include exercise, infection, autoimmunity, trauma, myocardial the tissue origins of cfDNA has the potential to be applied to any condition associated with APAP overdose is the most common cause of acute liver failure in the USA and Europe [38] .
Previous studies have suggested the utility of cfDNA as a clinical biomarker of cell death in a 3 0 1 range of clinical conditions [15, 18] , but cfDNA has not previously been studied as a 3 0 2 biomarker of liver damage in APAP overdose. We found that total concentration of cfDNA 3 0 3 robustly distinguished APAP overdose patients from healthy volunteers, suggesting that total 3 0 4
cfDNA concentration may reflect exposure to APAP. In overdose patients with raised ALT, 3 0 5 the increase in cfDNA concentration was greater than in those with normal ALT, although all 3 0 6 overdose patients had a higher cfDNA concentration than healthy volunteers. However, 3 0 7
whilst there was also a clear increase in the proportion of cfDNA that originated from liver in of increased GLDH in all overdose patients, both those with raised and normal ALT. but these data suggest that in APAP patients with normal ALT, the rise in total cfDNA and 3 1 3
GLDH was not liver-derived and may have been due to damage of tissues other than the 3 1 4 liver. Given that serum GLDH is a measure of mitochondrial damage [40] and that GLDH is tissues, for which further pre-clinical and clinical work is indicated to establish the source. Despite the novel approach of absolute and direct measurement of cfDNA, our study is least 10 mice was necessary to obtain sufficient material for ddPCR assay measurement. In Prior to wider application of cfDNA assays in the clinic, it will be important to understand 3 2 8
the sources of variability in cfDNA concentrations in healthy subjects and the origins of cfDNA in the presence of physiological stimuli such as exercise and common disorders (e.g. larger numbers will be needed for validation and formal assessment of sensitivity, specificity 3 3 8 and predictive power. candidate biomarker for stratification of APAP overdose patients. Ethics approval and consent to participate 3 5 8
Animal model work in this study was carried out in line with UK Home Office project and GLUD2 glutamate dehydrogenases in steroid producing tissues. Mol Cell Endocrinol. pink line shows the threshold between positive and negative droplets at fluorescence 5 1 8
